Explain this page
Arphra AIPlain-English read on Ionis Pharmaceuticals, Inc.’s valuation06-04today
- Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript3d
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors5d
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors5d
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors5d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $107.27 (+46.39%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.74% | -1.42% | -5.57% | +2.93% | -9.34% | -7.38% | +105.89% | +74.92% | +93.90% | +241.29% | +632.75% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$73.50
1 sh
Bid
$70.19
5 sh
Ask
$77.40
870 sh
Spread
$7.210
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 10, 2026
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directorsgurufocus.com·Jun 08, 2026
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directorsbusinesswire.com·Jun 08, 2026
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directorsbusinesswire.com·Jun 08, 2026
- Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcriptseekingalpha.com·Jun 05, 2026
- Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congressesbusinesswire.com·Jun 04, 2026
- Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congressesbusinesswire.com·Jun 04, 2026
- Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
Peers
No peer list available for IONS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|